title: Percutaneous ethanol and lipiodol injection therapy for hepatocellular carcinoma.
abstract: Radiofrequency ablation (RFA) therapy is of great significance in the treatment of hepatocellular carcinoma (HCC) or metastatic liver tumors. RFA is able to achieve widely coagulated necrosis in a few sessions without major complications. However, HCC cases exist that are resistant to RFA therapy for several reasons. In the present study, we performed injection of the mixture of ethanol and lipiodol (percutaneous ethanol-lipiodol injection therapy: PELIT) for HCCs that lacked clear visuality of the entire shape of the tumor by ultrasonography (US) or computed tomography (CT), or that were difficult to treat with RFA alone due to their locations in the liver or due to severe liver dysfunction of the patients. Local recurrence rates of HCC treated with PELIT were shown to be low in patients followed up for at least 4 months. In all patients treated with PELIT, lipiodol was accumulated in the entire region of the tumor after several trials of PELIT and the accumulation was kept for many months. The biopsy examination from the tumor treated with PELIT showed that HCC cells were totally destroyed by the PELIT. Although RFA therapy serves as a central role for the treatment of HCCs, PELIT, considered to be milder therapy, is likely to be important as a supportive treatment for HCCs and useful for the treatment of HCCs that are difficult to treat with RFA.
authors.affiliation: Third Department of Internal Medicine, Kagawa University School of Medicine, Miki-cho, Kita-gun, Kagawa 761-0793, Japan.
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Kurokohchi
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Masaki
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Miyauchi
authors.forename: Toshiharu
authors.initials: T
authors.lastname: Funaki
authors.forename: Hirohito
authors.initials: H
authors.lastname: Yoneyama
authors.forename: Hisaaki
authors.initials: H
authors.lastname: Miyoshi
authors.forename: Shuhei
authors.initials: S
authors.lastname: Yoshida
authors.forename: Takashi
authors.initials: T
authors.lastname: Himoto
authors.forename: Asahiro
authors.initials: A
authors.lastname: Morishita
authors.forename: Naohito
authors.initials: N
authors.lastname: Uchida
authors.forename: Seishiro
authors.initials: S
authors.lastname: Watanabe
authors.forename: Shigeki
authors.initials: S
authors.lastname: Kuriyama
mesh_terms: D000279:Administration, Cutaneous; D000368:Aged; D001706:Biopsy; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D017115:Catheter Ablation; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000008:administration & dosage / Q000627:therapeutic use; D000431:Ethanol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D007459:Iodized Oil / Q000008:administration & dosage / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D009362:Neoplasm Metastasis; D014057:Tomography, X-Ray Computed; D014463:Ultrasonography
chemical_list: D003287:Contrast Media; D000431:Ethanol; D007459:Iodized Oil